MannKind | MNKD - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Adma Biologics USD 477.32M 46.13M 2025-12
BioCryst Pharmaceuticals USD -119.15M 268.74M 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Insmed USD 738.98M 206.6M 2025-12
Karyopharm Therapeutics USD -269.26M 30.33M 2025-09
MacroGenics USD 55.59M 11.41M 2025-12
MannKind USD -51.02M 6.47M 2025-12
Merck USD 51.85B 2.79B 2025-09
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Novavax USD -127.75M 28.92M 2025-12
Novo Nordisk DKK 26.56B 111.98B 2025-06
Pfizer USD 92.8B 4.11B 2025-09
Sanofi EUR 71.71B 1.55B 2025-12
Xencor USD 635.59M 10.27M 2025-12